NVAX · Novavax, Inc.
$9.40
-3.09% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-57.4
Dividend yield
0.0%
Beta
2.44
Avg volume
6M
Employees
1K
Daily Change %
-3.09%
5 Days Change
-5.91%
10 Days Change
-16.52%
30 Days Change
-11.57%
60 Days Change
1.51%
Month to Day Change
-11.32%
Year to Day Change
39.88%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NVAX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
Citigroup
Sell$8.00
-14.9% vs priceJP Morgan
Underweight$6.00
-36.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Citigroup | Maintains | Sell | $7.00 → $8.00 |
| 2026-06-11 | BTIG | Reiterates | Buy | $19.00 |
| 2026-05-06 | TD Cowen | Maintains | Hold | $8.00 → $9.00 |
| 2026-02-27 | HC Wainwright & Co. | Maintains | Buy | $11.00 → $16.00 |
| 2026-01-20 | BTIG | Reiterates | Buy | $19.00 |
| 2025-11-18 | JP Morgan | Maintains | Underweight | $7.00 → $6.00 |
| 2025-11-10 | B. Riley Securities | Reiterates | Buy | $18.00 → $16.00 |
| 2025-11-04 | TD Cowen | Maintains | Hold | $8.00 → $7.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.8% below the 50-day MA ($10.31).
- bullish: Price vs 200-day MA: Trading 1.6% above the 200-day MA ($9.25).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.37) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($6.22) and high ($12.82).
NVAX Price Chart
Loading chart for NVAX…
Fundamentals
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.